title: Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch's membrane rupture.
abstract: OBJECTIVE
  Choroidal neovascularization (CNV) secondary to traumatic rupture of Bruch's membrane is a rare condition, without standardized treatment. Here we describe one case of CNV related to traumatic rupture of Bruch's membrane which was successfully treated with intravitreal injection of ranibizumab.
  
  
  METHODS
  A 14-year-old patient was referred for ocular contusion, complicating interpapillomacular rupture of Bruch's membrane in left eye. Indeed, a correct initial visual acuity, juxtafoveolar CNV appeared 4 months later on the border of Bruch's membrane rupture. The patient was treated with an off-label intravitreal ranibizumab because of worsening of visual acuity.
  
  
  RESULTS
  One month after intravitreal injection, visual acuity improved, from 20/40 to 20/25. At 12-month follow-up, visual acuity remained at 20/25, fundus examination. Fluorescein angiography, indocyanine green angiography and optic coherence tomography showed fibrotic evolution of CNV. The Bruch's membrane rupture remained stable. No side-effect of intravitreal injection of ranibizumab was observed.
  
  
  CONCLUSIONS
  For this patient affected with CNV secondary to traumatic Bruch's membrane, one single intravitreal ranibizumab injection was efficient, with 1-year follow-up.
authors.affiliation: Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, Université Paris 12 , Creteil 94000, France.
authors.forename: Feng
authors.initials: F
authors.lastname: Liang
authors.forename: Nathalie
authors.initials: N
authors.lastname: Puche
authors.forename: Gisèle
authors.initials: G
authors.lastname: Soubrane
authors.forename: Eric H
authors.initials: EH
authors.lastname: Souied
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016570:Bruch Membrane / Q000293:injuries* / Q000473:pathology; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004396:Coloring Agents; D005131:Eye Injuries / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D007267:Injections; D008297:Male; D000069579:Ranibizumab; D012421:Rupture; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D042461:Vascular Endothelial Growth Factor A; D007208:Indocyanine Green; D000069579:Ranibizumab